Polymer Factory announces last day of trading in BTA
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, OR CANADA OR ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW.
Polymer Factory Sweden AB (“Polymer Factory” or the “Company”) hereby announces that its pre-emptive rights issue of shares has been registered with the Swedish Company Registration office and trading in BTA (Betald Tecknad Aktie) will end on 27 March 2023 and stop day will be on 29 March 2023.
Polymer Factory conducted a rights issue of shares during the period 24 February 2023 – 10 March 2023, which provided the Company approx. SEK 6.1 million, before deduction of transaction related costs. A total of 3,839,024 shares have been issued through the rights issue. The rights issue has now been registered with the Swedish Companies Registration Office, and the last day of trading in BTA will be on 27 March and stop day will be 29 March 2023.The new shares are estimated to be delivered to each shareholder’s account on 31 March 2023. After the registration, the total number of shares in Polymer Factory amounts to 10,699,422 shares and the share capital amounts to approx. SEK 1,069,942.20.
Advisors
Sedermera Corporate Finance AB is the financial advisor and Markets & Corporate Law Nordic AB is the legal advisor to Polymer Factory in connection with the Rights Issue. Shark Communication AB is communications advisor and Nordic Issuing is the issuing agent.
For more information about the Rights Issue, please contact:
Sedermera Corporate Finance AB
Phone: +46 40 615 14 10
Email: cf@sedermera.se
www.sedermera.se
For more information about Polymer Factory, please contact:
Elin Mignérus, CEO
Phone: +46 (0) 79 300 27 76
E-mail: elin.mignerus@polymerfactory.com
Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company’s dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company’s vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company’s dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.